INTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intensity Therapeutics Inc. (INTS) is not a strong buy for a beginner, long-term investor at this time. The stock lacks clear positive momentum, has weak financial performance, and is facing financial challenges. While there is a bullish analyst price target, the lack of strong technical signals, negative financial trends, and no significant trading activity from insiders or hedge funds suggest a cautious approach. Hold for now and monitor for improvements in financials or stronger signals.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 38.401, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 5.873, with resistance at 7.241. No clear upward momentum is evident.
Analyst price target was significantly raised to $30 from $3.50, indicating potential long-term upside. The company has expanded its facility, which could enhance operational capabilities.
The company plans to offer up to $60 million in common stock to address financial challenges, which may dilute current shareholders. Financial performance is weak, with net income and EPS significantly declining YoY. The stock has no significant insider or hedge fund trading activity, and technical indicators are bearish.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped by -23.97% YoY to -$2,671,000, and EPS declined by -75.63% YoY to -1.55. Gross margin remained at 0 with no improvement.
Alliance Global raised the price target to $30 from $3.50 and maintains a Buy rating. The valuation is based on the company's pipeline, with specific values assigned to its compounds. However, this is speculative and contingent on future success.
